BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

InMed Pharmaceuticals Inc. – Material Contracts

NASDAQ: INM    
Share price (9/22/26): $1.39    
Market cap (9/22/26): $7.636 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.39
from S-4/A 10 pages July 23, 2026 Jerad G. Seurer Address: [***] [***] Email: [***] Re: Offer of Employment Dear Jerad: On Behalf of Mentari Therapeutics, Inc. (The “Company”), I Am Very Pleased to Offer You a Position as General Counsel & Corporate Secretary of the Company (The “Role”) Pursuant to This Letter Agreement (The “Agreement”), Provided You Accept Such Offer as Indicated by Your Signature Below
12/34/56
EX-10.38
from S-4/A 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $415,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation
12/34/56
EX-10.37
from S-4/A 11 pages Your Employment With the Company Will Commence as of July 20, 2026 (The “Effective Date”) and Shall Continue Until Terminated in Accordance With Section 5 (Such Period, the “Term”). Should You Not Commence Services Upon the Effective Date or if This Agreement Is Otherwise Terminated on or Prior to the Effective Date, You Hereby Agree That This Agreement Shall Be Void Ab Initio and of No Force or Effect. 1. Positions
12/34/56
EX-10.35
from S-4/A 44 pages License Agreement
12/34/56
EX-10.34
from S-4/A 35 pages Antibody Discovery and Option Agreement
12/34/56
EX-10.33
from S-4/A 27 pages Biologics Master Services Agreement
12/34/56
EX-10.32
from S-4/A 17 pages Cell Line License Agreement
12/34/56
EX-10.31
from S-4/A 4 pages Amendment No. 1 to Antibody Discovery and Option Agreement
12/34/56
EX-10.30
from S-4/A 34 pages Antibody Discovery and Option Agreement
12/34/56
EX-10.1
from 425 8 pages Amendment No. 1 to the Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 8 pages Amendment No. 1 to the Securities Purchase Agreement
12/34/56
EX-10.35
from S-4 11 pages Mentari Therapeutics, Inc. Warrant to Purchase Common Stock
12/34/56
EX-10.28
from S-4 14 pages Indemnification Agreement
12/34/56
EX-10.27
from S-4 11 pages Mentari Therapeutics, Inc. 2025 Equity Incentive Plan Stock Option Agreement [Incentive Stock Option // Nonstatutory Stock Option]
12/34/56
EX-10.26
from S-4 12 pages Mentari Therapeutics, Inc. 2025 Equity Incentive Plan Restricted Stock Agreement
12/34/56
EX-10.23
from S-4 2 pages First Amendment to the Mentari Therapeutics, Inc. 2025 Equity Incentive Plan
12/34/56
EX-10.22
from S-4 13 pages Mentari Therapeutics, Inc. 2025 Equity Incentive Plan
12/34/56
EX-10.5
from 425 42 pages Securities Purchase Agreement
12/34/56
EX-10.5
from 8-K 42 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 425 22 pages Contingent Value Rights Agreement
12/34/56